Citius Oncology, Inc. CTOR Amortization Of Inprocess Research And Development
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept ctor:AmortizationOfInprocessResearchAndDevelopment.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s amortization of inprocess research and development.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s amortization of inprocess research and development?
- Citius Oncology, Inc. (CTOR) reported amortization of inprocess research and development of $1.72M in Q1 2026.